|
⚲
|
| Keyboard |
| Platinum Management NY LLC
✚
|
|
|---|---|
| CRD # | 139405 |
| SEC # | 801-72514 |
| CIK # | 0001368616 |
| AUM | |
| Employees | 60 (50% Investors, 0% Brokers) |
| Phone | 212-582-2222 |
| Address | 250 West 55th Street New York, NY 10019-7599 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Blast Energy Services Inc | 1.3 | ||
| InspireMD Inc | 0.0 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Marbridge Energy Finance Fund II LLC | 2015-03-31 | 27.0 M | |
| PE | Marbridge Energy Finance Fund International II Ltd | 2015-03-31 | 3.0 M | |
| HF | Platinum Partners Black Elk Opportunities Fund LLC | 2013-12-03 | 35.7 M | |
| HF | Platnum Partners Black Elk Opportunities Fund Ltd | 2013-12-03 | 10.3 M | |
| HF | Longwood Finance Fund International Ltd | 2013-04-03 | 4.3 M | |
| HF | Longwood Finance Fund LLC | 2013-04-03 | 6.1 M | |
| HF | Bayberry Consumer Finance Fund International Ltd | 2012-03-30 | 22.7 M | |
| HF | Bayberry Consumer Finance Fund LLC | [2012-03-30] | 72.6 M | 37.7 M |
| Filed 2012-06-11 (D/A) · Exemption 506, 3(c), 3(c)(1) · Minimum $50,000 · Remaining Indefinite · Duration More than one year · Finder's Fee $57,615 · Net Assets Decline to Disclose | ||||
| HF | Platinum Partners Credit Opportunities Master Fund LP | [2012-03-30] | 100.9 M | 591.7 M |
| Filed 2015-09-02 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Platinum Partners Liquid Opportunity Master Fund LP | [2012-03-30] | 62.9 M | 27.4 M |
| Filed 2015-09-02 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Platinum Partners Value Arbitrage Fund LP | 2012-03-30 | 1,077.3 M | |
| HF | Pro Player Capital International Ltd | 2012-03-30 | 6.2 M | |
| HF | Pro Player Capital LLC | 2012-03-30 | ||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 14 | 1,700.8 |
| By Discretionary | ||
| Discretionary | 14 | 1,700.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 14 | 1,700.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 1,700.8 | |
| Total | 14 | 1,700.8 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| David Bree | Director | 428 | 100 | |
| Don Seymour | Director | 315 | 72 | |
| Don Seymor | Director | 6 | 4 | |
| Brian Jedwab | Executive Officer | 5 | 3 | |
| Mark Nordlicht | Director, Executive Officer | 9 | 2 | |
| Uri Landesman | Director, Executive Officer | 7 | 2 | |
| Abraham Biderman | Promoter | 5 | 2 | |
| Harvey Werblowsky | Executive Officer | 3 | 2 | |
| Gilad Kalter | Executive Officer | 3 | 2 | |
| Middlebury Securities LLC | Promoter | 2 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001368616] | |
| 3 | [0001368616] | |
| 4 | [0001368616] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.4B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Echo Therapeutics Inc ECTE
Warrants · derivative
|
2014-12-18 | Buy | 1 | $0.00 | |
|
Echo Therapeutics Inc ECTE
Series F Preferred Stock · derivative
|
2014-12-18 | Buy | 420,168 | $1.19 | 500,000 |
|
Navidea Biopharmaceuticals Inc NAVB
Common Stock, par value $0.001
|
2014-09-02 | Sell | 60,000 | $1.36 | 81,600 |
|
Echo Therapeutics Inc ECTE
Common Stock
|
2014-06-30 | Buy | 55,083 | $2.20 | 121,183 |
|
Echo Therapeutics Inc ECTE
Common Stock
|
2014-06-27 | Buy | 10,656 | $2.20 | 23,443 |
|
Echo Therapeutics Inc ECTE
Common Stock
|
2014-06-26 | Buy | 15,000 | $2.20 | 33,000 |
|
Echo Therapeutics Inc ECTE
Common Stock
|
2014-06-25 | Buy | 2,300 | $2.20 | 5,060 |
|
Echo Therapeutics Inc ECTE
Common Stock
|
2014-06-24 | Buy | 386 | $2.20 | 849 |
|
Echo Therapeutics Inc ECTE
Common Stock
|
2014-06-23 | Buy | 85 | $2.20 | 187 |
|
Echo Therapeutics Inc ECTE
Common Stock
|
2014-06-20 | Buy | 16,490 | $2.20 | 36,278 |
|
Echo Therapeutics Inc ECTE
Common Stock
|
2013-12-10 | Buy | 55,655 | $2.75 | 153,051 |
|
Echo Therapeutics Inc ECTE
Warrants · derivative
|
2013-12-10 | Buy | 1 | $0.00 | |
|
Echo Therapeutics Inc ECTE
Series E Preferred Stock · derivative
|
2013-12-10 | Buy | 1,398,890 | $2.75 | 3,846,948 |
|
Echo Therapeutics Inc ECTE
Series E Preferred Stock · derivative
|
2013-12-10 | Buy | 349,723 | $2.75 | 961,738 |
|
Echo Therapeutics Inc ECTE
Warrants · derivative
|
2013-12-10 | Buy | 1 | $0.00 | |
|
Echo Therapeutics Inc ECTE
Common Stock
|
2013-12-10 | Buy | 13,914 | $2.75 | 38,264 |